| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91f344ed3a42ef612ee6ec3c5778291d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 |
| filingDate |
2007-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daae38776a9e2614327cfd74c9147171 |
| publicationDate |
2009-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009197930-A1 |
| titleOfInvention |
Eyedrops |
| abstract |
It is intended to provide eyedrops which have an ocular tension-lowering effect and a hypotensive effect based on novel function mechanisms. The above-described eyedrops contain a muscle relaxant as the active ingredient and dantrolene sodium is preferably usable as the muscle relaxant employed as the active ingredient. The eyedrops lower the ocular tension via the relaxation of the extraocular muscle tension and lower the blood pressure via the relaxation of the sympathetic nerve tension, thereby exhibiting the ocular tension-lowering effect and the hypotensive effect. |
| priorityDate |
2006-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |